Potential liver toxicity is an important consideration for antiretroviral selection among patients coinfected with HIV and viral hepatitis (B and/or C). We sought to describe the hepatic safety profile of raltegravir in this population
Short communication[Abstract] Objectives. The aim of the study was to establish the risk of liver to...
Objective: To investigate the risk of hepatotoxicity after initiation of protease inhibi-tor-contain...
Introduction. Hepatotoxicity is a concern in HIV/hepatitis C virus (HCV) coinfected patients due to ...
Potential liver toxicity is an important consideration for antiretroviral selection among patients c...
Background: Patients with chronic hepatitis C virus (HCV) infection experience antiretroviral-associ...
The relationship between hepatic tolerance and hepatitis C virus (HCV) co-infection has not been ext...
The relationship between hepatic tolerance and hepatitis C virus (HCV) co-infection has not been ext...
• RAL was efficacious in HIV-infected patients with and without Hepatitis B and/or Hepatitis C co-i...
BackgroundThe risk of hepatotoxicity with antiretroviral therapy (ART) remains unknown. We determine...
BackgroundOne of the more clinically relevant co-morbidities in HIV-infected patients is the develop...
To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroi...
To evaluate the occurrence of hepatotoxicity in patients during antiretroviral therapy (ART) that co...
To assess the current frequency of ART-associated grade 3-4 transaminase elevations (TE) and grade 4...
BACKGROUND: Highly active antiretroviral therapy (HAART) is strongly effective in reducing morbidity...
Introduction: Although hepatotoxicity related to antiretroviral treatment (ART) has become less freq...
Short communication[Abstract] Objectives. The aim of the study was to establish the risk of liver to...
Objective: To investigate the risk of hepatotoxicity after initiation of protease inhibi-tor-contain...
Introduction. Hepatotoxicity is a concern in HIV/hepatitis C virus (HCV) coinfected patients due to ...
Potential liver toxicity is an important consideration for antiretroviral selection among patients c...
Background: Patients with chronic hepatitis C virus (HCV) infection experience antiretroviral-associ...
The relationship between hepatic tolerance and hepatitis C virus (HCV) co-infection has not been ext...
The relationship between hepatic tolerance and hepatitis C virus (HCV) co-infection has not been ext...
• RAL was efficacious in HIV-infected patients with and without Hepatitis B and/or Hepatitis C co-i...
BackgroundThe risk of hepatotoxicity with antiretroviral therapy (ART) remains unknown. We determine...
BackgroundOne of the more clinically relevant co-morbidities in HIV-infected patients is the develop...
To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroi...
To evaluate the occurrence of hepatotoxicity in patients during antiretroviral therapy (ART) that co...
To assess the current frequency of ART-associated grade 3-4 transaminase elevations (TE) and grade 4...
BACKGROUND: Highly active antiretroviral therapy (HAART) is strongly effective in reducing morbidity...
Introduction: Although hepatotoxicity related to antiretroviral treatment (ART) has become less freq...
Short communication[Abstract] Objectives. The aim of the study was to establish the risk of liver to...
Objective: To investigate the risk of hepatotoxicity after initiation of protease inhibi-tor-contain...
Introduction. Hepatotoxicity is a concern in HIV/hepatitis C virus (HCV) coinfected patients due to ...
DOI
Add to ORKG